Health and Fitness Health and Fitness
Fri, December 14, 2012
Thu, December 13, 2012
Wed, December 12, 2012
Tue, December 11, 2012
Mon, December 10, 2012
Sun, December 9, 2012
Sat, December 8, 2012
Fri, December 7, 2012
Thu, December 6, 2012
Wed, December 5, 2012
Tue, December 4, 2012
Mon, December 3, 2012
Sun, December 2, 2012
Sat, December 1, 2012
Fri, November 30, 2012
Thu, November 29, 2012
Wed, November 28, 2012
Tue, November 27, 2012
Mon, November 26, 2012
Sun, November 25, 2012
Fri, November 23, 2012
Thu, November 22, 2012
Wed, November 21, 2012
Tue, November 20, 2012
Mon, November 19, 2012

Vista Partners Publishes December 2012 Newsletter


Published on 2012-12-04 06:15:30 - Market Wire
  Print publication without navigation


December 04, 2012 09:00 ET

Vista Partners Publishes December 2012 Newsletter

Topics Include: Fiscal Cliff, Monthly Macroeconomic Commentary, Investment Ideas & More

SAN FRANCISCO, CA--(Marketwire - Dec 4, 2012) - [ Vista Partners ] ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of December. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst, Ross Silver, and monthly highlights of each covered small cap company. 

Ross Silver, Principal Analyst at Vista Partners, states in the newsletter, "For those of you unfamiliar with the 'Fiscal Cliff,' simply put it is a combination of tax cuts, tax breaks and spending cuts that will have a significant impact on the U.S. economic recovery, if it is not handled appropriately. Over 1,000 government programs, including the defense budget and Medicare, are in line for deep, automatic cuts that begin in January 2013. Should nothing happen, just about every economic expert alive believes we will go into a recession, unemployment will sky rocket and the stock market will head significantly lower."

Mr. Silver also highlights in the newsletter, "ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: [ ANX ]) continues to focus its resources on ANX-188 and the planned Phase 3 trial in sickle cell disease scheduled to commence by the end of 2012. Should the trial start within the next 27 days, we believe it may serve as a considerable catalyst to the share price as evidenced by a number of other biotech companies which have seen increases in their share price due to the anticipation of near term catalysts such as Celsion (ticker: CLSN)." 

To read more, please download the FREE December Newsletter available at [ http://www.vistapglobal.com ] and click the "download newsletter" icon. 

The Companies featured in the FREE December Newsletter are: Acorn Energy, Inc. (NASDAQ: [ ACFN ]), ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: [ ANX ]), Algae.Tec Limited, Auxilio Inc., Oculus Innovative Sciences, Inc. (NASDAQ: [ OCLS ]), Ohr Pharmaceutical, Inc. (OTCQB: [ OHRP ]), and PositiveID Corporation. Other companies mentioned are Roche, Novartis, Selexys, Regeneron, Pfizer, Lufthansa and others.

To download the FREE December Newsletter, please visit [ http://www.vistapglobal.com ] and click "Download Research & Newsletter" or [ CLICK HERE ] to gain access. 

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking.

Please follow us on [ Twitter @VistaPResearch ]& [ Facebook ]at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.

Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website: [ www.vistapglobal.com ].



Publication Contributing Sources